An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid

Trial Profile

An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Bertilimumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 04 Aug 2017 According to an Immune Pharmaceuticals Inc media release, preliminary data from this trial were presented at the American Academy of Dermatology 2017 Annual Meeting.
    • 04 Aug 2017 According to an Immune Pharmaceuticals Inc media release, patients have been enrolled at Mount Sinai Medical Center in New York City and at four sites in Israel. Company expect to complete this study late 2017 and subsequent publication early in 2018.
    • 28 Feb 2017 According to an Immune Pharmaceuticals Inc media release, based on the preliminary results from the study the company has submitted a request for orphan drug designation for Bertilimumab in bullous pemphigoid.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top